Stem Bromelain

Summary

Stem Bromelain (CHEMBL4298054) is an approved enzyme; indicated across 4 conditions including burn and basal cell carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• Indications: 4 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298054
Name	Stem Bromelain
Type	Enzyme
Max phase	4

Also known as: Anacaulase, Anacaulase-bcdb, Bromelain stem bromelain, Debrase, Ec 3.4.22.32, Escharex, Nexobrid, Pineapple stem bromelain, Stem bromelain, STEM BROMELAIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
burn	3	MONDO:0043519	EFO:0009516
basal cell carcinoma	1	MONDO:0020804	EFO:0004193

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	3
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06568627	PHASE3	RECRUITING	A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
NCT02148705	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns
NCT02278718	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care
NCT05157763	PHASE1/PHASE2	RECRUITING	A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
NCT06690177	PHASE2	NOT_YET_RECRUITING	Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers
NCT02020746	PHASE2	COMPLETED	Efficacy and Safety Study of EscharEx to Treat (Debride) Hard to Heal Wounds
NCT03588130	PHASE2	COMPLETED	A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers
NCT04817228	PHASE2	COMPLETED	A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers
NCT04040660	Not specified	APPROVED_FOR_MARKETING	Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).